A Study to Evaluate the Efficacy, Safety, and Immunogenicity of SCT1000 in Healthy Women Aged 18-45 Years

NCT06041061 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

18000

Enrollment

INDUSTRY

Sponsor class

Conditions

HPV InfectioN
HPV-Related Carcinoma

Interventions

BIOLOGICAL: Recombinant 14-Valent Human Papillomavirus Vaccine（Insect Cell）
BIOLOGICAL: placebo

Sponsor

Sinocelltech Ltd.

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]